Employing AAV immunogenicity predictive models for risk assessment of gene therapy products

Time: 9:30 am
day: Day Two


  • Learn about the use of novel assays and platforms that can be implemented during the developability of gene therapy products
  • Develop and implement novel predictive immune assays for product characterization and risk assessment of critical quality attributes (CQA) testing
  • Understand the mechanism related to AAV-mediated immune responses which can provide potential solutions to modulate vector immunogenicity